China approves clinical trials for CanSino's inhaled COVID-19 vaccine
BEIJING -- China's drug authority has approved clinical tests for an inhaled COVID-19 vaccine co-developed by domestic company CanSino Biologics, the Agence France-Presse (AFP) reported on Tuesday.
The clinical trial application of the vaccine, jointly developed by CanSino and the Beijing Institute of Biotechnology, was approved by the National Medical Products Administration (NMPA) on Monday, the pharmaceutical firm said in a filing on the Hong Kong stock exchange on Tuesday.
The safety and efficacy of the inhaled vaccine remain "subject to confirmation," the firm said.
The NMPA conditionally approved a recombinant vaccine for COVID-19 made by CanSino last month, which marked the first approved adenoviral vector vaccine for COVID-19.
More than 85.85 million doses of COVID-19 vaccines have been administered across China as of Wednesday, the National Health Commission said Thursday.
- Chinese nationals evacuated from Iran arrive in Beijing
- Latest global rankings show shift in global research landscape
- CPC members work against the clock to restore normal life in rain-hit Hunan
- Ceremony commemorates legendary ancestor of the Chinese civilization Fuxi
- Former KMT chair leads Taiwan delegation to honor Fuxi, Chinese culture
- Shanghai conference discusses occupational mental health in China
